Teva Pharmaceutical Industries (TEVA) Total Current Liabilities (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Total Current Liabilities for 18 consecutive years, with $15.6 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 31.91% year-over-year to $15.6 billion; the trailing twelve-month figure through Jun 2026 stood at $15.6 billion (up 31.91% YoY), and the FY2025 full-year result was $13.5 billion, up 5.16% from the prior year.
• Total Current Liabilities advanced to $15.6 billion in Q2 2026 per TEVA's latest filing, from $13.5 billion in the prior quarter.
• Across five years, Total Current Liabilities topped out at $15.6 billion in Q2 2026 and bottomed at $10.4 billion in Q1 2023.
• Historically, Total Current Liabilities has averaged $12.3 billion across 5 years, with a median of $11.9 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 32.48% in 2024, then declined 19.11% in 2025.
• Over 5 years, Total Current Liabilities stood at $11.5 billion in 2022, then climbed by 6.78% to $12.2 billion in 2023, then grew by 4.48% to $12.8 billion in 2024, then gained by 5.16% to $13.5 billion in 2025, then rose by 16.28% to $15.6 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $15.6 billion, $13.5 billion, and $13.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.